Research shows that HFpEF, a common type of heart failure, occurs because heart cells can’t remove calcium fast enough when adrenaline kicks in during exercise. According to Gram Research analysis of this 2026 study, the heart’s inability to clear calcium during stress slows down the heart’s relaxation between beats, reducing blood flow and causing exercise intolerance. This calcium removal defect happens at the cellular level and could become a new target for heart failure treatments.
Researchers discovered why people with a specific type of heart failure struggle during exercise, even though their hearts pump normally at rest. Using mice with obesity and high blood pressure, scientists found that the heart’s cells can’t remove calcium quickly enough when the body needs extra energy. This calcium buildup slows down how fast the heart relaxes between beats, making it harder to exercise. According to Gram Research analysis, this finding could lead to new treatments that help the heart relax better and improve quality of life for millions of heart failure patients.
Key Statistics
A 2026 research article published in The Journal of Physiology found that HFpEF mice developed diastolic dysfunction and exercise intolerance despite maintaining normal ejection fraction, demonstrating that preserved pumping strength does not mean a healthy heart.
In the 2026 study, HFpEF mice showed impaired calcium removal in response to adrenaline stimulation at the cellular level, which directly correlated with slowed heart relaxation and reduced cardiac output during stress.
Research from 2026 demonstrated that the calcium handling defect in HFpEF appears consistently across three levels of measurement: in the whole heart, in heart tissue, and in individual heart cells, strengthening evidence that calcium removal is central to the disease.
The Quick Take
- What they studied: Why people with heart failure that preserves normal pumping strength (HFpEF) can’t exercise well and get tired easily
- Who participated: Laboratory mice that were made to have obesity and high blood pressure to mimic human heart disease
- Key finding: The heart’s cells can’t remove calcium fast enough when adrenaline kicks in during exercise, which slows the heart’s relaxation and reduces blood flow
- What it means for you: This research identifies a new target for heart failure treatments that could help patients exercise better and feel less tired, though human trials are still needed
The Research Details
Scientists created mice with obesity and high blood pressure to develop a specific type of heart failure called HFpEF. They then studied these mice at three different levels: looking at the whole heart with ultrasound, examining heart tissue in a lab, and studying individual heart cells under a microscope. At each level, they measured how well the heart relaxed and how it responded when the body released adrenaline (the stress hormone that normally helps your heart work harder during exercise).
The researchers used special imaging techniques to watch calcium moving in and out of heart cells. Calcium is crucial for heart muscle contractions, but the heart also needs to remove calcium quickly to relax between beats. They compared how well sick hearts removed calcium compared to healthy hearts, especially when adrenaline was present.
This multi-level approach was important because it showed the same problem appearing at every scale, from the whole organ down to individual cells. This consistency makes the findings more reliable and suggests the calcium problem is truly central to the disease.
Most heart failure research focuses on hearts that pump weakly. But HFpEF is different: the heart pumps normally, yet patients still feel terrible and can’t exercise. This has made HFpEF hard to treat because doctors didn’t fully understand what was broken. By studying the problem at the cellular level, researchers can identify specific targets for new medicines, rather than just treating symptoms.
This study used a well-established animal model that mimics human disease through obesity and high blood pressure. The researchers measured the same outcomes at multiple levels (whole heart, tissue, and individual cells), which strengthens confidence in the results. The study was published in The Journal of Physiology, a respected peer-reviewed journal. However, this is animal research, so results may not directly translate to humans without further testing.
What the Results Show
The HFpEF mice developed several problems similar to human heart failure patients: their hearts became enlarged, they couldn’t exercise as long as healthy mice, and their hearts didn’t relax properly between beats. Importantly, their hearts still pumped out a normal amount of blood at rest, which is the defining feature of HFpEF.
When researchers looked at the calcium handling in heart cells, they found something surprising. At rest, calcium moved normally in sick hearts. But when adrenaline was added (simulating exercise or stress), healthy hearts quickly removed the calcium to allow proper relaxation. In HFpEF hearts, this calcium removal was much slower, like a traffic jam that only appears during rush hour.
This calcium backup directly caused the heart to relax slowly, which reduced how much blood could be pumped out with each beat during exercise. The mice couldn’t exercise because their hearts couldn’t keep up with the body’s demands. This same pattern appeared whether researchers looked at the whole heart, heart tissue, or individual cells, making the finding very convincing.
The study also showed that the basic calcium handling at rest was normal in HFpEF hearts, which means the problem isn’t with the heart’s resting state. The defect only appears when adrenaline tries to speed up the calcium removal process. This suggests that specific proteins responsible for removing calcium during stress are not working properly. Additionally, the reduced exercise capacity in the mice directly correlated with the calcium removal problem, showing a clear cause-and-effect relationship.
Previous research knew that HFpEF hearts relax slowly, but scientists weren’t sure why. Some thought it was stiffness in the heart muscle itself, while others suspected problems with calcium. This study provides strong evidence that calcium handling during stress is a major culprit. The finding that resting calcium handling is normal but stress-induced calcium removal is impaired is a new insight that narrows down where to look for treatments.
This research used mice, not humans, so the findings must be confirmed in human studies before new treatments can be developed. The study doesn’t identify which specific proteins are broken or why they fail during stress. Additionally, the mice were created through diet and blood pressure changes, which may not perfectly match all the ways human HFpEF develops. The study also doesn’t test whether fixing the calcium problem would actually improve the mice’s exercise capacity.
The Bottom Line
This research suggests that future heart failure treatments should focus on improving calcium removal during stress, particularly by enhancing the adrenaline response system in heart cells. However, these are early-stage findings from animal studies. Patients with HFpEF should continue following their doctor’s current treatment plans while waiting for new therapies to be developed and tested in humans. Current confidence level: moderate for the scientific mechanism, but low for clinical recommendations until human trials are completed.
People with HFpEF or those at risk (obesity, high blood pressure) should care about this research because it could lead to better treatments. Cardiologists and heart researchers should pay attention because it identifies a specific therapeutic target. People with other types of heart failure should note this is specific to HFpEF and may not apply to their condition.
New drugs based on this research would likely take 5 to 10 years to develop and test in humans before becoming available. In the near term (1 to 2 years), researchers will likely test whether directly improving calcium removal helps these mice exercise better. If successful, human clinical trials could begin within 3 to 5 years.
Frequently Asked Questions
What is HFpEF and why is it different from regular heart failure?
HFpEF means the heart pumps normally but can’t relax properly between beats. Unlike regular heart failure where the heart is weak, HFpEF hearts appear strong on standard tests, making it harder to diagnose and treat. This 2026 research shows the problem is calcium buildup during stress.
Why can’t people with HFpEF exercise like healthy people?
During exercise, the body releases adrenaline to speed up the heart. In HFpEF, the heart cells can’t remove calcium fast enough when adrenaline arrives, so the heart can’t relax quickly enough to fill with blood. This reduces blood flow and causes fatigue.
Could this research lead to new treatments for heart failure?
Yes. This 2026 study identifies calcium removal as a specific target for new drugs. Researchers can now develop treatments to improve how heart cells clear calcium during stress, potentially helping HFpEF patients exercise better and feel less tired.
How soon will new HFpEF treatments based on this research be available?
Early-stage research like this typically takes 5 to 10 years to become a treatment. Researchers will first test whether fixing calcium removal helps mice, then conduct human trials. New drugs could reach patients within a decade if development succeeds.
Should I change my treatment if I have HFpEF?
No. Continue following your doctor’s current treatment plan. This research is preliminary and hasn’t been tested in humans yet. Talk to your cardiologist about participating in future clinical trials testing new calcium-targeting therapies.
Want to Apply This Research?
- Users with HFpEF should track exercise tolerance by recording how long they can walk or perform light activity before feeling tired, noting the specific time in minutes each day
- Set a daily goal to gradually increase light activity (walking, gentle movement) by 1 to 2 minutes per week, logging each session to monitor improvement as new treatments become available
- Create a weekly summary comparing exercise duration and fatigue levels to establish a baseline and track changes over months, sharing this data with your cardiologist to guide treatment decisions
This article describes early-stage research in mice and does not represent approved medical treatments. HFpEF is a serious condition requiring medical supervision. Do not change your heart failure treatment based on this research. Consult your cardiologist before starting any new exercise program or treatment. This research identifies a potential future therapeutic target but has not been tested in humans. Always follow your doctor’s recommendations for managing heart failure.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.